KCM
CRDF icon

Kennedy Capital Management’s Cardiff Oncology CRDF Stock Holding History

Kennedy Capital Management’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-168,902
Closed -$419K – 607
2022
Q1 		$419K Sell
168,902
-1,545
-0.9% -$5.46K 0.01% 563
2021
Q4 		$1.02M Sell
170,447
-5,380
-3% -$32.1K 0.02% 515
2021
Q3 		$1.17M Sell
175,827
-89,301
-34% -$561K 0.03% 510
2021
Q2 		$1.76M Sell
265,128
-3,245
-1% -$27.5K 0.04% 488
2021
Q1 		$2.48M Buy
268,373
+110,838
+70% +$1.35M 0.05% 495
2020
Q4 		$2.83M Buy
+157,535
New +$2.77M 0.06% 458

Other funds holding CRDF

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Kennedy Capital Management's CRDF Position: Q2 2022 in Review

Kennedy Capital Management sold out of Cardiff Oncology (CRDF) in Q2 2022, closing a stake of 168,902 shares — an estimated $419K sold.

Kennedy Capital Management first reported a position in CRDF in Q4 2020 and held it in 6 quarters. The position peaked at $2.83M in Q4 2020. 67 funds tracked by Wall St. Rank hold CRDF as of Q2 2022.

  • Kennedy Capital Management reported no remaining Cardiff Oncology position as of Q2 2022 after selling out during the quarter.
  • Kennedy Capital Management sold 168,902 Cardiff Oncology shares in Q2 2022, an estimated $419K.
  • Kennedy Capital Management first reported a position in Cardiff Oncology in Q4 2020 and held it in 6 quarters.
  • Kennedy Capital Management's Cardiff Oncology position peaked at $2.83M in Q4 2020.
  • 67 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2022.

Based on Kennedy Capital Management's 13F filing for Q2 2022, filed 10 Aug 2022.